How long does it take for avatrombopag (Su Kexin) to take effect and the efficacy observation

Avatrombopag (Avatrombopag, trade name: Doptelet) is an oral small-molecule thrombopoietin (TPO) receptor agonist that can promote the proliferation and differentiation of bone marrow megakaryocytes, thereby increasing platelet production. Generally speaking, the platelet count begins to rise about 5—8 days after patients start taking it, and most people can reach the expected level within 2 weeks. Therefore, clinical practice is to prescribe medication in advance before surgery or risk of bleeding.

For patients with thrombocytopenia due to chronic liver disease, avatrombopag is usually taken continuously for 5 days before surgery, and the platelet count reaches the peak about 4—8 days after stopping the drug, thus reducing the risk of intraoperative and postoperative bleeding. For patients with chronic immune thrombocytopenia (ITP), they need to take it regularly for a long time. Usually, obvious effects can be observed within 2—3 weeks. However, individual differences are large, and routine blood monitoring is needed to judge the drug response.

The efficacy of avatrombopag varies among individuals. Some patients respond quickly to the drug and have a significant increase in platelet count, while some patients take longer to stabilize. Platelet counts need to be monitored regularly during treatment to avoid excessive increases that may lead to the risk of thrombosis. If the platelet level does not meet expectations for a long time, the dose should be adjusted under the guidance of a doctor or alternative treatment options should be considered.

Patients should strictly follow the doctor's instructions while taking avatrombopag, and should not increase or decrease the dose or stop the drug at will. For long-term use, the doctor will determine the course of treatment based on the efficacy and side effects. Most clinical trials have shown that the drug can significantly reduce blood transfusion and bleeding events and improve patients' quality of life. However, during the observation period of the efficacy, if headache, fatigue or thrombosis-related symptoms occur, you should seek medical treatment and be evaluated in time.

Reference materials:https://www.drugs.com/